CLVS
Price:
$0.0812
Market Cap:
$0
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through ...[Read more]
Industry
Biotechnology
IPO Date
2011-11-16
Stock Exchange
NASDAQ
Ticker
CLVS
According to Clovis Oncology, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 1.58. This represents a change of 43.34% compared to the average of 1.10 of the last 4 quarters.
The mean historical Current Ratio of Clovis Oncology, Inc. over the last ten years is 6.75. The current 1.58 Current Ratio has changed 2.24% with respect to the historical average. Over the past ten years (40 quarters), CLVS's Current Ratio was at its highest in in the June 2013 quarter at 31.09. The Current Ratio was at its lowest in in the September 2022 quarter at 0.14.
Average
6.75
Median
5.85
Minimum
1.58
Maximum
15.68
Discovering the peaks and valleys of Clovis Oncology, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 80.56%
Maximum Annual Current Ratio = 15.68
Minimum Annual Increase = -40.82%
Minimum Annual Current Ratio = 1.58
Year | Current Ratio | Change |
---|---|---|
2021 | 1.58 | -5.88% |
2020 | 1.68 | -38.96% |
2019 | 2.75 | -39.49% |
2018 | 4.55 | -40.82% |
2017 | 7.69 | 80.56% |
2016 | 4.26 | -40.35% |
2015 | 7.14 | -30.54% |
2014 | 10.28 | -34.44% |
2013 | 15.68 | 31.64% |
2012 | 11.91 | -7.43% |
The current Current Ratio of Clovis Oncology, Inc. (CLVS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
2.01
5-year avg
3.65
10-year avg
6.75
Clovis Oncology, Inc.’s Current Ratio is
Company | Current Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Clovis Oncology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Clovis Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Clovis Oncology, Inc.'s Current Ratio?
How is the Current Ratio calculated for Clovis Oncology, Inc. (CLVS)?
What is the highest Current Ratio for Clovis Oncology, Inc. (CLVS)?
What is the 3-year average Current Ratio for Clovis Oncology, Inc. (CLVS)?
What is the 5-year average Current Ratio for Clovis Oncology, Inc. (CLVS)?
How does the current Current Ratio for Clovis Oncology, Inc. (CLVS) compare to its historical average?